US Edition
UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
NEW YORK, JUL 25 – Klotho Neurosciences aims to slow biological aging by expanding into muscle strength and bone health, targeting multiple age-related disorders linked to declining Klotho levels.
- This past week, Klotho Neurosciences announced it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity.
- Amid evidence of age-linked molecular decline, Klotho levels decline with age, motivating Klotho Neurosciences, Inc.'s strategic expansion.
- Klotho CEO Dr. Joseph Sinkule said, 'We have begun manufacturing and clinical development of KLTO-101 and KLTO-202,' while the portfolio includes DNA and RNA therapeutics and diagnostics.
- Several uncertainties could affect outcomes, and forward-looking statements are based on expectations and assumptions, highlighting risks in implementing business plans and technologies.
- Beyond its core programs, Klotho Neurosciences seeks to expand into technologies supporting healthy aging, outlining research focused on complementing its proprietary 'anti-aging' Klotho platform, positioning the company to advance longevity initiatives.
Insights by Ground AI
Does this summary seem wrong?
63 Articles
63 Articles
Coverage Details
Total News Sources63
Leaning Left6Leaning Right6Center21Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 18%
C 64%
R 18%
Factuality
To view factuality data please Upgrade to Premium
